2I9 Stock Overview A venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. More details
Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Karolinska Development AB (publ) Competitors Price History & Performance
Summary of share price highs, lows and changes for Karolinska Development Historical stock prices Current Share Price SEK 0.063 52 Week High SEK 0.14 52 Week Low SEK 0.061 Beta 0.20 1 Month Change -8.61% 3 Month Change -25.12% 1 Year Change -49.27% 3 Year Change -86.92% 5 Year Change -80.62% Change since IPO -92.25%
Recent News & Updates
Karolinska Development AB Announces Changes to Chairman Dec 19
Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the Board Dec 11
Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023) Nov 17
Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines Nov 15
An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV). Sep 23
Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023) Sep 01 See more updates
Karolinska Development AB Announces Changes to Chairman Dec 19
Karolinska Development AB (Publ) Announces Resignation of Hans Wigzell as Chairman of the Board Dec 11
Third quarter 2024 earnings released: kr0.04 loss per share (vs kr0.044 profit in 3Q 2023) Nov 17
Karolinska Development AB Announces CEO Changes to its Portfolio Company SVF Vaccines Nov 15
An undisclosed buyer acquired 15% stake in Henlez ApS from Karolinska Development AB (publ) (OM:KDEV). Sep 23
Second quarter 2024 earnings released: kr0.059 loss per share (vs kr0.086 profit in 2Q 2023) Sep 01 Karolinska Development AB (publ) to Report Fiscal Year 2024 Final Results on Mar 21, 2025
New major risk - Share price stability May 28
First quarter 2024 earnings released Apr 28
Karolinska Development AB (Publ) Announces That Björn Cochlovius Has Declined Re-Election Apr 16
Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022) Mar 25
New major risk - Revenue and earnings growth Mar 24
Chief Executive Officer recently bought €7.2k worth of stock Feb 28
Full year 2023 earnings released: EPS: kr0.02 (vs kr0.34 loss in FY 2022) Feb 18 Karolinska Development AB (publ) to Report First Half, 2024 Results on Aug 30, 2024
New major risk - Revenue and earnings growth Nov 19 Karolinska Development AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 40.3 million. Nov 09
Ossdsign Receives FDA Clearance for the Use of OssDsign Catalyst in Interbody Cages in Spinal Surgery Sep 21
Second quarter 2023 earnings released: EPS: kr0.086 (vs kr0.083 loss in 2Q 2022) Aug 27
Full year 2022 earnings released: kr0.34 loss per share (vs kr0.97 profit in FY 2021) Mar 28
Full year 2022 earnings released: kr3.43 loss per share (vs kr0.97 profit in FY 2021) Feb 18
Karolinska Development AB (Publ) Announces That Its Portfolio Company Dilafor’S Extended Clinical Phase 2B Study with the Drug Candidate Tafoxiparin Has Resulted in Further Positive Data Feb 15
Third quarter 2022 earnings released Nov 19 Karolinska Development AB (publ) to Report First Half, 2023 Results on Aug 25, 2023
Karolinska Development AB (publ), Annual General Meeting, May 16, 2023 Nov 18
Less than half of directors are independent Nov 16
Modus Therapeutics AB's Portfolio Company Modus Therapeutics Completes Recruitment in a Clinical Phase 1B Study of Sevuparin Sep 28
Karolinska Development AB Announces Chief Financial Officer Changes Sep 07 Karolinska Development’s portfolio company Modus Therapeutics initiates inclusion in phase 1 study of sevuparin in pediatric patients with severe malaria Sep 03
Second quarter 2022 earnings released Aug 20
Karolinska Development's Portfolio Company Initiated A Clinical Phase 1 Program with PN-6047 Aug 20 Karolinska Development AB (publ) to Report Fiscal Year 2022 Results on Feb 17, 2023
First quarter 2022 earnings released May 01
Less than half of directors are independent Apr 27
Karolinska Development AB (Publ) Announces Portfolio Company Ossdsign Completes Patient Enrolment to the Top Fusion Study Apr 26
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Feb 28 Karolinska Development AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 377.64874 million. Feb 08
Organon & Co. (NYSE:OGN) completed the acquisition of Forendo Pharma Ltd from Karolinska Development AB (publ) (OM:KDEV), KD Co-Investment Fund KB, fund managed by Karolinska Development AB (publ) and others. Dec 14
Karolinska Development’s Portfolio Company Modus Therapeutics Initiates Phase 1b Trial of Its Drug Candidate Sevuparin Dec 02
Third quarter 2021 earnings released Nov 19
Investor sentiment improved over the past week Nov 16
Second quarter 2021 earnings released: EPS kr1.23 (vs kr0.012 in 2Q 2020) Aug 21
Karolinska Development AB Announces the US Food and Drug Administration Issued A Clinical Hold for Aprea Therapeutics Clinical Program Aug 13
Karolinska Development AB (publ) (OM:KDEV) acquired additional 21% minority stake in Anacardio AB. Jun 18
First quarter 2021 earnings released May 01
Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019) Mar 31
CFO & Deputy CEO Fredrik Jarrsten has left the company Mar 10 Karolinska Development AB Announces CFO Changes
Karolinska Development Appoints Johan Dighed as Deputy CEO Feb 27
Karolinska Development AB (publ) Announces Management Appointments Feb 20
Full year 2020 earnings released: kr1.18 loss per share (vs kr4.10 profit in FY 2019) Feb 12
New 90-day low: €0.21 Nov 19
New 90-day low: €0.23 Oct 29
New 90-day low: €0.23 Sep 17
New 90-day low - €0.23 Sep 02
Karolinska Development AB (publ) (OM:KDEV) acquired 5% stake in Svenska Vaccinfabriken Produktion AB. Jul 31 Shareholder Returns 2I9 DE Pharmaceuticals DE Market 7D -7.0% -2.2% -2.0% 1Y -49.3% -15.6% 6.9%
See full shareholder returns
Return vs Market: 2I9 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 2I9's price volatile compared to industry and market? 2I9 volatility 2I9 Average Weekly Movement 22.9% Pharmaceuticals Industry Average Movement 5.5% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 2I9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2I9's weekly volatility has increased from 15% to 23% over the past year.
About the Company Karolinska Development AB (publ) is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in the Nordic region with a focus on Sweden, Iceland, Norway, Finland, and Denmark.
Show more Karolinska Development AB (publ) Fundamentals Summary How do Karolinska Development's earnings and revenue compare to its market cap? 2I9 fundamental statistics Market cap €23.31m Earnings (TTM ) -€2.48m Revenue (TTM ) €163.36k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 2I9 income statement (TTM ) Revenue SEK 1.88m Cost of Revenue SEK 0 Gross Profit SEK 1.88m Other Expenses SEK 30.41m Earnings -SEK 28.53m
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
Earnings per share (EPS) -0.11 Gross Margin 100.00% Net Profit Margin -1,519.01% Debt/Equity Ratio 0%
How did 2I9 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 02:16 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Karolinska Development AB (publ) is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Johan Löchen ABG Sundal Collier Sponsored Espen Jørgensen DNB Markets Sachin Soni Kempen & Co. NV
Show 4 more analysts 
